- Investigator
- Francesco Franchi
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
Research at a glance
Top areas of exploration
- Platelet Aggregation Inhibitors , 78 publications
- Percutaneous Coronary Intervention , 46 publications
- Purinergic P2Y Receptor Antagonists , 41 publications
- Clopidogrel , 34 publications
Research activity
Active clinical trials
- Investigator
- Francesco Franchi
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
- Investigator
- Francesco Franchi
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
My publications
Filter publications
126 publications
2024
Clopidogrel-Mediated P2Y12 Inhibition According to Renal Function in Patients With Diabetes Mellitus and CAD
JACC: Basic to Translational Science
Publisher's site2024
Effectiveness of Clopidogrel vs Alternative P2Y12 Inhibitors Based on the ABCD-GENE Score
Journal of the American College of Cardiology
Publisher's site2024
P2Y12 Inhibition in Patients Requiring Oral Anticoagulation after Percutaneous Coronary Intervention: The SWAP-AC–2 Study
JACC: Cardiovascular Interventions
Publisher's site2024
Switching from Dual Antiplatelet Therapy with Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition with Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study.
Thrombosis and haemostasis
PubMed • Publisher's site2024
The Lipid-Platelet Interplay: Unraveling the Effects of PCSK9 Inhibition on Platelet Reactivity.
Thrombosis and haemostasis
PubMed • Publisher's site